1
|
Heterozygous Loss of KRIT1 in Mice Affects Metabolic Functions of the Liver, Promoting Hepatic Oxidative and Glycative Stress. Int J Mol Sci 2022; 23:ijms231911151. [PMID: 36232456 PMCID: PMC9570113 DOI: 10.3390/ijms231911151] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 09/16/2022] [Accepted: 09/19/2022] [Indexed: 12/04/2022] Open
Abstract
KRIT1 loss-of-function mutations underlie the pathogenesis of Cerebral Cavernous Malformation (CCM), a major vascular disease affecting the central nervous system (CNS). However, KRIT1 is also expressed outside the CNS and modulates key regulators of metabolic and oxy-inflammatory pathways, including the master transcription factor FoxO1, suggesting a widespread functional significance. Herein, we show that the KRIT1/FoxO1 axis is implicated in liver metabolic functions and antioxidative/antiglycative defenses. Indeed, by performing comparative studies in KRIT1 heterozygous (KRIT1+/−) and wild-type mice, we found that KRIT1 haploinsufficiency resulted in FoxO1 expression/activity downregulation in the liver, and affected hepatic FoxO1-dependent signaling pathways, which are markers of major metabolic processes, including gluconeogenesis, glycolysis, mitochondrial respiration, and glycogen synthesis. Moreover, it caused sustained activation of the master antioxidant transcription factor Nrf2, hepatic accumulation of advanced glycation end-products (AGEs), and abnormal expression/activity of AGE receptors and detoxifying systems. Furthermore, it was associated with an impairment of food intake, systemic glucose disposal, and plasma levels of insulin. Specific molecular alterations detected in the liver of KRIT1+/− mice were also confirmed in KRIT1 knockout cells. Overall, our findings demonstrated, for the first time, that KRIT1 haploinsufficiency affects glucose homeostasis and liver metabolic and antioxidative/antiglycative functions, thus inspiring future basic and translational studies.
Collapse
|
2
|
Genetics and Vascular Biology of Brain Vascular Malformations. Stroke 2022. [DOI: 10.1016/b978-0-323-69424-7.00012-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
3
|
Riolo G, Ricci C, Battistini S. Molecular Genetic Features of Cerebral Cavernous Malformations (CCM) Patients: An Overall View from Genes to Endothelial Cells. Cells 2021; 10:704. [PMID: 33810005 PMCID: PMC8005105 DOI: 10.3390/cells10030704] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 03/18/2021] [Accepted: 03/18/2021] [Indexed: 02/07/2023] Open
Abstract
Cerebral cavernous malformations (CCMs) are vascular lesions that affect predominantly microvasculature in the brain and spinal cord. CCM can occur either in sporadic or familial form, characterized by autosomal dominant inheritance and development of multiple lesions throughout the patient's life. Three genes associated with CCM are known: CCM1/KRIT1 (krev interaction trapped 1), CCM2/MGC4607 (encoding a protein named malcavernin), and CCM3/PDCD10 (programmed cell death 10). All the mutations identified in these genes cause a loss of function and compromise the protein functions needed for maintaining the vascular barrier integrity. Loss of function of CCM proteins causes molecular disorganization and dysfunction of endothelial adherens junctions. In this review, we provide an overall vision of the CCM pathology, starting with the genetic bases of the disease, describing the role of the proteins, until we reach the cellular level. Thus, we summarize the genetics of CCM, providing a description of CCM genes and mutation features, provided an updated knowledge of the CCM protein structure and function, and discuss the molecular mechanisms through which CCM proteins may act within endothelial cells, particularly in endothelial barrier maintenance/regulation and in cellular signaling.
Collapse
Affiliation(s)
| | | | - Stefania Battistini
- Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy; (G.R.); (C.R.)
| |
Collapse
|
4
|
Ercoli J, Finetti F, Woodby B, Belmonte G, Miracco C, Valacchi G, Trabalzini L. KRIT1 as a possible new player in melanoma aggressiveness. Arch Biochem Biophys 2020; 691:108483. [PMID: 32735866 DOI: 10.1016/j.abb.2020.108483] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 06/30/2020] [Accepted: 07/02/2020] [Indexed: 11/27/2022]
Abstract
Krev interaction trapped protein 1 (KRIT1) is a scaffold protein known to form functional complexes with distinct proteins, including Malcavernin, PDCD10, Rap1 and others. It appears involved in several cellular signaling pathways and exerts a protective role against inflammation and oxidative stress. KRIT1 has been studied as a regulator of endothelial cell functions and represents a determinant in the pathogenesis of Cerebral Cavernous Malformation (CCM), a cerebrovascular disease characterized by the formation of clusters of abnormally dilated and leaky blood capillaries, which predispose to seizures, neurological deficits and intracerebral hemorrhage. Although KRIT1 is ubiquitously expressed, few studies have described its involvement in pathologies other than CCM including cancer. Cutaneous melanoma represents the most fatal skin cancer due to its high metastatic propensity. Despite the numerous efforts made to define the signaling pathways activated during melanoma progression, the molecular mechanisms at the basis of melanoma growth, phenotype plasticity and resistance to therapies are still under investigation.
Collapse
Affiliation(s)
- Jasmine Ercoli
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Italy
| | - Federica Finetti
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Italy
| | - Brittany Woodby
- Plants for Human Health Institute, NC Research Campus, NC State University, NC, USA
| | - Giuseppe Belmonte
- Unit of Pathological Anatomy, Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy
| | - Clelia Miracco
- Unit of Pathological Anatomy, Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy
| | - Giuseppe Valacchi
- Plants for Human Health Institute, NC Research Campus, NC State University, NC, USA; Dept. of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, Italy; Department of Food and Nutrition, Kyung Hee University, Seoul, South Korea.
| | - Lorenza Trabalzini
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Italy.
| |
Collapse
|
5
|
de Vos IJHM, Vreeburg M, Koek GH, van Steensel MAM. Review of familial cerebral cavernous malformations and report of seven additional families. Am J Med Genet A 2016; 173:338-351. [PMID: 27792856 DOI: 10.1002/ajmg.a.38028] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Accepted: 07/18/2016] [Indexed: 11/11/2022]
Abstract
Cerebral cavernous malformations are vascular anomalies of the central nervous system characterized by clusters of enlarged, leaky capillaries. They are caused by loss-of-function mutations in KRIT1, CCM2, or PDCD10. The proteins encoded by these genes are involved in four partially interconnected signaling pathways that control angiogenesis and endothelial permeability. Cerebral cavernous malformations can occur sporadically, or as a familial autosomal dominant disorder (FCCM) with incomplete clinical and neuroradiological penetrance and great inter-individual variability. Although the clinical course is unpredictable, symptoms typically present during adult life and include headaches, focal neurological deficits, seizures, and potentially fatal stroke. In addition to neural lesions, extraneural cavernous malformations have been described in familial disease in several tissues, in particular the skin. We here present seven novel FCCM families with neurologic and cutaneous lesions. We review histopathological and clinical features and provide an update on the pathophysiology of cerebral cavernous malformations and associated cutaneous vascular lesions. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Ivo J H M de Vos
- Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, The Netherlands.,School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center+, Maastricht, The Netherlands.,Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Maaike Vreeburg
- Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, The Netherlands.,School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center+, Maastricht, The Netherlands
| | - Ger H Koek
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, The Netherlands
| | - Maurice A M van Steensel
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.,School of Medicine and School of Life Sciences, University of Dundee, Dundee, United Kingdom
| |
Collapse
|
6
|
Meliton A, Meng F, Tian Y, Shah AA, Birukova AA, Birukov KG. Role of Krev Interaction Trapped-1 in Prostacyclin-Induced Protection against Lung Vascular Permeability Induced by Excessive Mechanical Forces and Thrombin Receptor Activating Peptide 6. Am J Respir Cell Mol Biol 2016; 53:834-43. [PMID: 25923142 DOI: 10.1165/rcmb.2014-0376oc] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Mechanisms of vascular endothelial cell (EC) barrier regulation during acute lung injury (ALI) or other pathologies associated with increased vascular leakiness are an active area of research. Adaptor protein krev interaction trapped-1 (KRIT1) participates in angiogenesis, lumen formation, and stabilization of EC adherens junctions (AJs) in mature vasculature. We tested a role of KRIT1 in the regulation of Rho-GTPase signaling induced by mechanical stimulation and barrier dysfunction relevant to ventilator-induced lung injury and investigated KRIT1 involvement in EC barrier protection by prostacyclin (PC). PC stimulated Ras-related protein 1 (Rap1)-dependent association of KRIT1 with vascular endothelial cadherin at AJs, with KRIT1-dependent cortical cytoskeletal remodeling leading to EC barrier enhancement. KRIT1 knockdown exacerbated Rho-GTPase activation and EC barrier disruption induced by pathologic 18% cyclic stretch and thrombin receptor activating peptide (TRAP) 6 and attenuated the protective effects of PC. In the two-hit model of ALI caused by high tidal volume (HTV) mechanical ventilation and TRAP6 injection, KRIT1 functional deficiency in KRIT1(+/-) mice increased basal lung vascular leak and augmented vascular leak and lung injury caused by exposure to HTV and TRAP6. Down-regulation of KRIT1 also diminished the protective effects of PC against TRAP6/HTV-induced lung injury. These results demonstrate a KRIT1-dependent mechanism of vascular EC barrier control in basal conditions and in the two-hit model of ALI caused by excessive mechanical forces and TRAP6 via negative regulation of Rho activity and enhancement of cell junctions. We also conclude that the stimulation of the Rap1-KRIT1 signaling module is a major mechanism of vascular endothelial barrier protection by PC in the injured lung.
Collapse
Affiliation(s)
- Angelo Meliton
- Lung Injury Center and Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Fanyong Meng
- Lung Injury Center and Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Yufeng Tian
- Lung Injury Center and Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Alok A Shah
- Lung Injury Center and Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Anna A Birukova
- Lung Injury Center and Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Konstantin G Birukov
- Lung Injury Center and Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois
| |
Collapse
|
7
|
Kim H, Pawlikowska L, Su H, Young WL. Genetics and Vascular Biology of Angiogenesis and Vascular Malformations. Stroke 2016. [DOI: 10.1016/b978-0-323-29544-4.00012-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
8
|
van den Berg MCW, Burgering BMT. CCM1 and the second life of proteins in adhesion complexes. Cell Adh Migr 2015; 8:146-57. [PMID: 24714220 DOI: 10.4161/cam.28437] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
It is well recognized that a number of proteins present within adhesion complexes perform discrete signaling functions outside these adhesion complexes, including transcriptional control. In this respect, β-catenin is a well-known example of an adhesion protein present both in cadherin complexes and in the nucleus where it regulates the TCF transcription factor. Here we discuss nuclear functions of adhesion complex proteins with a special focus on the CCM-1/KRIT-1 protein, which may turn out to be yet another adhesion complex protein with a second life.
Collapse
Affiliation(s)
- Maaike C W van den Berg
- Center for Molecular Medicine; Dept. Molecular Cancer Research; University Medical Center Utrecht; The Netherlands
| | - Boudewijn M T Burgering
- Center for Molecular Medicine; Dept. Molecular Cancer Research; University Medical Center Utrecht; The Netherlands
| |
Collapse
|
9
|
Retinal cavernous hemangioma: fifty-two years of clinical follow-up with clinicopathologic correlation. Retina 2015; 34:1253-7. [PMID: 24849703 DOI: 10.1097/iae.0000000000000232] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE To report long-term follow-up and histopathology of a retinal cavernous hemangioma and to review the literature on this subject. METHODS A newborn girl was noted immediately after birth to a have hyphema and vitreous hemorrhage in her left eye. The bleeding recurred throughout childhood and the etiology was not determined. Upon referral at age 22, a large retinal cavernous hemangioma was first recognized and recurrent hemorrhages continued, eventually leading to pain and secondary glaucoma. The patient declined treatment. At age 52, the hemangioma was stable in size, but ocular pain and blindness necessitated enucleation. RESULTS During the 52-year course, the fundus mass did not enlarge, but numerous episodes of hyphema and vitreous hemorrhage led to chronic glaucoma and eventual blindness. The main histopathologic finding in the disorganized globe was a retinal mass composed of large endothelial-lined vascular channels with thin walls, typical of a retinal cavernous hemangioma. The tumor extended anteriorly into the ciliary body, explaining the recurrent hyphemas. Additional chronic features included extensive fibrosis of the entire anterior segment, iris, and retina with proliferative vitreoretinopathy and widespread intraocular hemosiderosis from chronic hemorrhage. The patient has been free of pain since enucleation. CONCLUSION Retinal cavernous hemangioma is a congenital stationary lesion that can cause recurrent intraocular hemorrhage, fibrosis, glaucoma, pain, and blindness, requiring enucleation. Retinal cavernous should be included in the differential diagnosis of childhood hyphema and vitreous hemorrhage.
Collapse
|
10
|
Chrzanowska-Wodnicka M. Distinct functions for Rap1 signaling in vascular morphogenesis and dysfunction. Exp Cell Res 2013; 319:2350-9. [PMID: 23911990 DOI: 10.1016/j.yexcr.2013.07.022] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Revised: 07/18/2013] [Accepted: 07/21/2013] [Indexed: 01/27/2023]
Abstract
Rap1 signaling is important for both major processes of vessel formation: vasculogenesis, or de novo vessel formation, and angiogenesis, sprouting of new vessels from pre-existing ones. We provide an overview of genetic studies in mice and zebrafish and discuss some of the proposed underlying mechanisms derived from cellular models, with particular emphasis on Rap1's role in angiogenesis, maintenance of endothelial barrier and connection with cerebral cavernous malformation (CCM), a neurological deficit that leads to seizures and lethal stroke. Lastly, we provide a brief summary of studies in cardiac and smooth muscle cells, where the Epac-Rap1 signaling axis is emerging as an important regulator of contractility.
Collapse
|
11
|
Orso F, Balzac F, Marino M, Lembo A, Retta SF, Taverna D. miR-21 coordinates tumor growth and modulates KRIT1 levels. Biochem Biophys Res Commun 2013; 438:90-6. [PMID: 23872064 PMCID: PMC3750217 DOI: 10.1016/j.bbrc.2013.07.031] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Accepted: 07/10/2013] [Indexed: 12/15/2022]
Abstract
miR-21 targets KRIT1. miR-21 and KRIT1 expression anticorrelate in human breast tumors. KRIT1 is involved in miR-21-mediated tumor cell growth.
miR-21 is overexpressed in tumors and it displays oncogenic activity. Here, we show that expression of miR-21 in primary tumors anticorrelates with KRIT1/CCM1, an interacting partner of the Ras-like GTPase Rap1, involved in Cerebral Cavernous Malformations (CCM). We present evidences that miR-21 silences KRIT1 by targeting its mRNA 3′UTR and that this interaction is involved in tumor growth control. In fact, miR-21 over-expression or KRIT1 knock-down promote anchorage independent tumor cell growth compared to controls, whereas the opposite is observed when anti-miR-21 or KRIT1 overexpression are employed. Our findings suggest that miR-21 promotes tumor cell growth, at least in part, by down-modulating the potential tumor suppressor KRIT1.
Collapse
Affiliation(s)
- Francesca Orso
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
- Center for Complex Systems in Molecular Biology and Medicine, University of Torino, Torino, Italy
| | - Fiorella Balzac
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Marco Marino
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Antonio Lembo
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | | | - Daniela Taverna
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
- Center for Complex Systems in Molecular Biology and Medicine, University of Torino, Torino, Italy
- Corresponding author. Address: MBC and Department Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Torino, Italy. Fax: +39 011 670 6432.
| |
Collapse
|
12
|
Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Tournier-Lasserve E. Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis. Trends Mol Med 2013; 19:302-8. [PMID: 23506982 DOI: 10.1016/j.molmed.2013.02.004] [Citation(s) in RCA: 129] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Revised: 02/18/2013] [Accepted: 02/18/2013] [Indexed: 11/18/2022]
Abstract
Cerebral cavernous malformations (CCMs) are vascular lesions that can occur sporadically or as a consequence of inherited loss-of-function mutations, predominantly in the genes CCM1 (KRIT1), CCM2 (MGC4607, OSM, Malcavernin), or CCM3 (PDCD10, TFAR15). Inherited, familial CCM is characterized by the development of multiple lesions throughout a patient's life leading to recurrent cerebral hemorrhages. Recently, roles for the CCM proteins in maintaining vascular barrier functions and quiescence have been elucidated, and in this review we summarize the genetics and pathophysiology of this disease and discuss the molecular mechanisms through which CCM proteins may act within blood vessels.
Collapse
Affiliation(s)
- Andreas Fischer
- Vascular Signaling and Cancer (A270), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
| | | | | | | | | |
Collapse
|
13
|
Agarwal A, Sternberg P. Cavernous Hemangioma. Retina 2013. [DOI: 10.1016/b978-1-4557-0737-9.00129-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management. Eur J Hum Genet 2011; 20:134-40. [PMID: 21829231 DOI: 10.1038/ejhg.2011.155] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Cerebral cavernous (or capillary-venous) malformations (CCM) have a prevalence of about 0.1-0.5% in the general population. Genes mutated in CCM encode proteins that modulate junction formation between vascular endothelial cells. Mutations lead to the development of abnormal vascular structures.In this article, we review the clinical features, molecular and genetic basis of the disease, and management.
Collapse
|
15
|
Abstract
Vascular anomalies are localized defects of vascular development. Most of them occur sporadically (ie, there is no familial history of lesions, yet in a few cases clear inheritance is observed). These inherited forms are often characterized by multifocal lesions that are mainly small in size and increase in number with patients' age. The authors review the known (genetic) causes of vascular anomalies and call attention to the concept of Knudson's double-hit mechanism to explain incomplete penetrance and large clinical variation in expressivity observed in inherited vascular anomalies. The authors also discuss the identified pathophysiological pathways involved in vascular anomalies and how it has opened the doors toward a more refined classification of vascular anomalies and the development of animal models that can be tested for specific molecular therapies.
Collapse
Affiliation(s)
- Laurence M. Boon
- Center for Vascular Anomalies, Division of Plastic Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium
- Laboratory of Human Molecular Genetics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | - Fanny Ballieux
- Center for Vascular Anomalies, Division of Plastic Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Miikka Vikkula
- Laboratory of Human Molecular Genetics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
16
|
Yadla S, Jabbour PM, Shenkar R, Shi C, Campbell PG, Awad IA. Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution. Neurosurg Focus 2010; 29:E4. [PMID: 20809762 DOI: 10.3171/2010.5.focus10121] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Tremendous insight into the molecular and genetic pathogenesis of cerebral cavernous malformations (CCMs) has been gained over the past 2 decades. This includes the identification of 3 distinct genes involved in familial CCMs. Still, a number of unanswered questions regarding the process from gene mutation to vascular malformation remain. It is becoming more evident that the disruption of interendothelial junctions and ensuing vascular hyperpermeability play a principal role. The purpose of this review is to summarize the current understanding of CCM genes, associated proteins, and functional pathways. Promising molecular and genetic therapies targeted at identified molecular aberrations are discussed as well.
Collapse
Affiliation(s)
- Sanjay Yadla
- Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | | | | | | | | | | |
Collapse
|
17
|
KRIT1 regulates the homeostasis of intracellular reactive oxygen species. PLoS One 2010; 5:e11786. [PMID: 20668652 PMCID: PMC2910502 DOI: 10.1371/journal.pone.0011786] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2010] [Accepted: 06/25/2010] [Indexed: 01/06/2023] Open
Abstract
KRIT1 is a gene responsible for Cerebral Cavernous Malformations (CCM), a major cerebrovascular disease characterized by abnormally enlarged and leaky capillaries that predispose to seizures, focal neurological deficits, and fatal intracerebral hemorrhage. Comprehensive analysis of the KRIT1 gene in CCM patients has suggested that KRIT1 functions need to be severely impaired for pathogenesis. However, the molecular and cellular functions of KRIT1 as well as CCM pathogenesis mechanisms are still research challenges. We found that KRIT1 plays an important role in molecular mechanisms involved in the maintenance of the intracellular Reactive Oxygen Species (ROS) homeostasis to prevent oxidative cellular damage. In particular, we demonstrate that KRIT1 loss/down-regulation is associated with a significant increase in intracellular ROS levels. Conversely, ROS levels in KRIT1−/− cells are significantly and dose-dependently reduced after restoration of KRIT1 expression. Moreover, we show that the modulation of intracellular ROS levels by KRIT1 loss/restoration is strictly correlated with the modulation of the expression of the antioxidant protein SOD2 as well as of the transcriptional factor FoxO1, a master regulator of cell responses to oxidative stress and a modulator of SOD2 levels. Furthermore, we show that the KRIT1-dependent maintenance of low ROS levels facilitates the downregulation of cyclin D1 expression required for cell transition from proliferative growth to quiescence. Finally, we demonstrate that the enhanced ROS levels in KRIT1−/− cells are associated with an increased cell susceptibility to oxidative DNA damage and a marked induction of the DNA damage sensor and repair gene Gadd45α, as well as with a decline of mitochondrial energy metabolism. Taken together, our results point to a new model where KRIT1 limits the accumulation of intracellular oxidants and prevents oxidative stress-mediated cellular dysfunction and DNA damage by enhancing the cell capacity to scavenge intracellular ROS through an antioxidant pathway involving FoxO1 and SOD2, thus providing novel and useful insights into the understanding of KRIT1 molecular and cellular functions.
Collapse
|
18
|
He Y, Zhang H, Yu L, Gunel M, Boggon TJ, Chen H, Min W. Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal 2010; 3:ra26. [PMID: 20371769 DOI: 10.1126/scisignal.2000722] [Citation(s) in RCA: 130] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Cerebral cavernous malformations (CCMs) are human vascular malformations caused by mutations in three genes of unknown function: CCM1, CCM2, and CCM3. CCM3, also known as PDCD10 (programmed cell death 10), was initially identified as a messenger RNA whose abundance was induced by apoptotic stimuli in vitro. However, the in vivo function of CCM3 has not been determined. Here, we describe mice with a deletion of the CCM3 gene either ubiquitously or specifically in the vascular endothelium, smooth muscle cells, or neurons. Mice with global or endothelial cell-specific deletion of CCM3 exhibited defects in embryonic angiogenesis and died at an early embryonic stage. CCM3 deletion reduced vascular endothelial growth factor receptor 2 (VEGFR2) signaling in embryos and endothelial cells. In response to VEGF stimulation, CCM3 was recruited to and stabilized VEGFR2, and the carboxyl-terminal domain of CCM3 was required for the stabilization of VEGFR2. Indeed, the CCM3 mutants found in human patients lacking the carboxyl-terminal domain were labile and were unable to stabilize and activate VEGFR2. These results demonstrate that CCM3 promotes VEGFR2 signaling during vascular development.
Collapse
Affiliation(s)
- Yun He
- Interdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, 10 Amistad Street, New Haven, CT 06520, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Reddy S, Gorin MB, McCannel TA, Tsui I, Straatsma BR. Novel KRIT1/CCM1 mutation in a patient with retinal cavernous hemangioma and cerebral cavernous malformation. Graefes Arch Clin Exp Ophthalmol 2010; 248:1359-61. [PMID: 20306072 PMCID: PMC2910301 DOI: 10.1007/s00417-010-1329-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2009] [Revised: 01/19/2010] [Accepted: 02/04/2010] [Indexed: 11/11/2022] Open
Abstract
Backround Retinal cavernous hemangiomas are rare vascular anomalies, and can be associated with cerebral cavernous malformations (CCM). Distinct mutations have been reported in patients who have both CCMs and retinal cavernous hemangiomas. Methods Fluorescein angiography, spectral domain optical coherence tomography, and genetic testing were performed on a patient with a retinal cavernous hemangioma and a CCM. Results Our patient was heterozygous in the KRIT1/CCM1 gene for a frameshift mutation, c.1088delC. This would be predicted to result in premature protein termination. Discussion We have identified a novel mutation in the KRIT1/CCM1 gene in a patient with both CCM and retinal cavernous hemangioma. We hypothesize that the occurrence of retinal cavernous hemangiomas and CCMs is underlaid by a common mechanism present in the KRIT1/CCM1 gene.
Collapse
Affiliation(s)
- Shantan Reddy
- NYU Langone Medical Center, 530 First Avenue, New York, NY 10016, USA.
| | | | | | | | | |
Collapse
|
20
|
Chan AC, Li DY, Berg MJ, Whitehead KJ. Recent insights into cerebral cavernous malformations: animal models of CCM and the human phenotype. FEBS J 2010; 277:1076-83. [PMID: 20096037 DOI: 10.1111/j.1742-4658.2009.07536.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Cerebral cavernous malformations are common vascular lesions of the central nervous system that predispose to seizures, focal neurologic deficits and potentially fatal hemorrhagic stroke. Human genetic studies have identified three genes associated with the disease and biochemical studies of these proteins have identified interaction partners and possible signaling pathways. A variety of animal models of CCM have been described to help translate the cellular and biochemical insights into a better understanding of disease mechanism. In this minireview, we discuss the contributions of animal models to our growing understanding of the biology of cavernous malformations, including the elucidation of the cellular context of CCM protein actions and the in vivo confirmation of abnormal endothelial cell-cell interactions. Challenges and progress towards developing a faithful model of CCM biology are reviewed.
Collapse
Affiliation(s)
- Aubrey C Chan
- Molecular Medicine Program, University of Utah, Salt Lake City, UT 84112, USA
| | | | | | | |
Collapse
|
21
|
Glading AJ, Ginsberg MH. Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. Dis Model Mech 2009; 3:73-83. [PMID: 20007487 DOI: 10.1242/dmm.003293] [Citation(s) in RCA: 100] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
KRIT1, also called CCM1, is a member of a multiprotein complex that contains the products of the CCM2 and PDCD10 (also known as CCM3) loci. Heterozygous loss of any of the genes that encode these proteins leads to cerebral cavernous malformations (CCM), which are vascular lesions that are found in around 0.5% of humans. KRIT1 mediates the stabilization of beta-catenin-containing endothelial cell-cell junctions downstream of the Rap1 GTPase. Here, we report that Rap1 and KRIT1 are negative regulators of canonical beta-catenin signaling in mice and that hemizygous Krit1 deficiency exacerbates beta-catenin-driven pathologies. Depletion of endothelial KRIT1 caused beta-catenin to dissociate from vascular endothelial (VE)-cadherin and to accumulate in the nucleus with consequent increases in beta-catenin-dependent transcription. Activation of Rap1 inhibited beta-catenin-dependent transcription in confluent endothelial cells; this effect required the presence of intact cell-cell junctions and KRIT1. These effects of KRIT1 were not limited to endothelial cells; the KRIT1 protein was expressed widely and its depletion increased beta-catenin signaling in epithelial cells. Moreover, a reduction in KRIT1 expression also increased beta-catenin signaling in vivo. Hemizygous deficiency of Krit1 resulted in a ~1.5-fold increase in intestinal polyps in the Apc(Min/+) mouse, which was associated with increased beta-catenin-driven transcription. Thus, KRIT1 regulates beta-catenin signaling, and Krit1(+/-) mice are more susceptible to beta-catenin-driven intestinal adenomas.
Collapse
Affiliation(s)
- Angela J Glading
- Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
| | | |
Collapse
|
22
|
London NR, Whitehead KJ, Li DY. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 2009; 12:149-58. [PMID: 19172407 DOI: 10.1007/s10456-009-9130-z] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2008] [Accepted: 01/06/2009] [Indexed: 01/13/2023]
Abstract
The function of the endothelium is to provide a network to allow delivery of oxygen and nutrients to tissues throughout the body. This network comprises adjacent endothelial cells that utilize adherens junction proteins such as vascular endothelial cadherin (VE-cadherin) to maintain the appropriate level of vascular permeability. The disruption of VE-cadherin interactions during pathologic settings can lead to excessive vascular leak with adverse effects. Endogenous cell signaling systems have been defined, which help to maintain the proper level of vascular stability. Perhaps the best described system is Angiopoietin-1 (Ang-1). Ang-1 acting through its receptor Tie2 generates a well-described set of signaling events ultimately leading to enhanced vascular stability. In this review, we will focus on what is known about additional endogenous cell signaling systems that stabilize the vasculature, and using Ang-1/Tie2 as a model, we will address where our understanding of these additional systems is lacking.
Collapse
Affiliation(s)
- Nyall R London
- Department of Medicine, University of Utah, 15 N 2030 E, Salt Lake City, UT 84112-5330, USA
| | | | | |
Collapse
|
23
|
Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 2008; 18:919-30. [PMID: 19088123 DOI: 10.1093/hmg/ddn430] [Citation(s) in RCA: 208] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Cerebral cavernous malformations (CCMs) are vascular anomalies of the central nervous system, comprising dilated blood-filled capillaries lacking structural support. The lesions are prone to rupture, resulting in seizures or hemorrhagic stroke. CCM can occur sporadically, manifesting as solitary lesions, but also in families, where multiple lesions generally occur. Familial cases follow autosomal-dominant inheritance due to mutations in one of three genes, CCM1/KRIT1, CCM2/malcavernin or CCM3/PDCD10. The difference in lesion burden between familial and sporadic CCM, combined with limited molecular data, suggests that CCM pathogenesis may follow a two-hit molecular mechanism, similar to that seen for tumor suppressor genes. In this study, we investigate the two-hit hypothesis for CCM pathogenesis. Through repeated cycles of amplification, subcloning and sequencing of multiple clones per amplicon, we identify somatic mutations that are otherwise invisible by direct sequencing of the bulk amplicon. Biallelic germline and somatic mutations were identified in CCM lesions from all three forms of inherited CCMs. The somatic mutations are found only in a subset of the endothelial cells lining the cavernous vessels and not in interstitial lesion cells. These data suggest that CCM lesion genesis requires complete loss of function for one of the CCM genes. Although widely expressed in the different cell types of the brain, these data also suggest a unique role for the CCM proteins in endothelial cell biology.
Collapse
Affiliation(s)
- Amy L Akers
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
| | | | | | | | | |
Collapse
|
24
|
Hogan BM, Bussmann J, Wolburg H, Schulte-Merker S. ccm1 cell autonomously regulates endothelial cellular morphogenesis and vascular tubulogenesis in zebrafish. Hum Mol Genet 2008; 17:2424-32. [PMID: 18469344 DOI: 10.1093/hmg/ddn142] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Cerebral cavernous malformations (CCMs) are a prevalent class of vascular anomalies characterized by thin-walled clusters of malformed blood vessels in the brain. Heritable forms are caused by mutations in CCM1, CCM2 and CCM3, but despite the importance of these factors in vascular biology, an understanding of their molecular and cellular functions remains elusive. Here we describe the characterization of a zebrafish embryonic model of CCM. Loss of ccm1 in zebrafish embryos leads to severe and progressive dilation of major vessels, despite normal endothelial cell fate and number. Vascular dilation in ccm1 mutants is accompanied by progressive spreading of endothelial cells and thinning of vessel walls despite ultrastructurally normal cell-cell contacts. Zebrafish ccm2 mutants display comparable vascular defects. Finally, we show that ccm1 function is cell autonomous, suggesting that it is endothelial cellular morphogenesis that is regulated by CCM proteins during development and pathogenesis.
Collapse
Affiliation(s)
- Benjamin M Hogan
- Hubrecht Institute-KNAW and University Medical Centre Utrecht, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands
| | | | | | | |
Collapse
|
25
|
Tanriover G, Boylan AJ, DiLuna ML, Pricola KL, Louvi A, Gunel M. PDCD10, THE GENE MUTATED IN CEREBRAL CAVERNOUS MALFORMATION 3, IS EXPRESSED IN THE NEUROVASCULAR UNIT. Neurosurgery 2008; 62:930-8; discussion 938. [DOI: 10.1227/01.neu.0000318179.02912.ca] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Gamze Tanriover
- Department of Histology and Embryology, Akdeniz University, Antalya, Turkey, and Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
| | - Arianne J. Boylan
- Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
| | - Michael L. DiLuna
- Department of Neurosurgery and Program on Neurogenetics, Yale University School of Medicine, New Haven, Connecticut
| | - Katie L. Pricola
- Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
| | - Angeliki Louvi
- Department of Neurosurgery and Program on Neurogenetics, Yale University School of Medicine, New Haven, Connecticut
| | - Murat Gunel
- Departments of Neurosurgery and Neurobiology and Program on Neurogenetics, Yale University School of Medicine, New Haven, Connecticut
| |
Collapse
|
26
|
Abstract
Cerebral cavernous malformations (CCM) are vascular malformations that can occur as a sporadic or a familial autosomal dominant disorder. Clinical and cerebral MRI data on large series of patients with a genetic form of the disease are now available. In addition, three CCM genes have been identified: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. These recent developments in clinical and molecular genetics have given us useful information about clinical care and genetic counselling and have broadened our understanding of the mechanisms of this disorder.
Collapse
|
27
|
Abstract
Cerebral cavernous malformation (CCM) is a vascular malformation causing neurological problems, such as headaches, seizures, focal neurological deficits, and cerebral haemorrhages. CCMs can occur sporadically or as an autosomal dominant condition with variable expression and incomplete penetrance. Familial forms have been linked to three chromosomal loci, and loss of function mutations have been identified in the KRIT1/CCM1, MGC4607/CCM2, and PDCD10/CCM3 genes. Recently, many new pieces of data have been added to the CCM puzzle. It has been shown that the three CCM genes are expressed in neurones rather than in blood vessels. The interaction between CCM1 and CCM2, which was expected on the basis of their structure, has also been proven, suggesting a common functional pathway. Finally, in a large series of KRIT1 mutation carriers, clinical and neuroradiological features have been characterised. These data should lead to more appropriate follow up, treatment, and genetic counselling. The recent developments will also help to elucidate the precise pathogenic mechanisms leading to CCM, contributing to a better understanding of normal and pathological angiogenesis and to the development of targeted treatment.
Collapse
Affiliation(s)
- N Revencu
- Laboratory of Human Molecular Genetics, Christian de Duve Institute of Cellular Pathology, Université catholique de Louvain, Avenue Hippocrate 74, BP 75.39, B-1200 Brussels, Belgium
| | | |
Collapse
|
28
|
Plummer NW, Squire TL, Srinivasan S, Huang E, Zawistowski JS, Matsunami H, Hale LP, Marchuk DA. Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm Genome 2006; 17:119-28. [PMID: 16465592 DOI: 10.1007/s00335-005-0098-8] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2005] [Accepted: 09/14/2005] [Indexed: 11/24/2022]
Abstract
Cerebral cavernous malformations are vascular defects of the central nervous system consisting of clusters of dilated vessels that are subject to frequent hemorrhaging. The genes mutated in three forms of autosomal dominant cerebral cavernous malformations have been cloned, but it remains unclear which cell type is ultimately responsible for the lesion. In this article we describe mice with a gene trap insertion in the Ccm2 gene. Consistent with the human phenotype, heterozygous animals develop cerebral vascular malformations, although penetrance is low. Beta-galactosidase activity in heterozygous brain and in situ hybridization in wild-type brain revealed Ccm2 expression in neurons and choroid plexus but not in vascular endothelium of small vessels in the brain. The expression pattern of Ccm2 is similar to that of the Ccm1 gene and its interacting protein ICAP1 (Itgb1bp1). These data suggest that cerebral cavernous malformations arise as a result of defects in the neural parenchyma surrounding the vascular endothelial cells in the brain.
Collapse
Affiliation(s)
- Nicholas W Plummer
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Petit N, Blécon A, Denier C, Tournier-Lasserve E. Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. Gene Expr Patterns 2006; 6:495-503. [PMID: 16455310 DOI: 10.1016/j.modgep.2005.11.001] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2005] [Revised: 10/14/2005] [Accepted: 11/03/2005] [Indexed: 11/24/2022]
Abstract
Cerebral Cavernous Malformation (CCM) is a disease characterized by capillary-venous lesions mostly located in the central nervous system. It occurs both as a sporadic and hereditary autosomal dominant condition. Three CCM genes have been identified and shown to encode the KRIT1 (CCM1), MGC4607 (CCM2) and PDCD10 (CCM3) proteins whose functions are so far unknown. In an attempt to get some insight into the role of the 3 CCM genes, we used in situ hybridization to conduct a comparative analysis of their expression pattern at several time points during murine embryonic, postnatal and adult stages particularly within the central nervous system. A strong expression of the 3 Ccm genes was detected in the various neuronal cell layers of the brain, cerebellum and spinal cord, from embryonic to adult life. By E14.5 a moderate labelling was observed in the heart, arterial and venous large vessels with all 3 Ccm probes. Ccm2 and Ccm3 mRNAs, but not Ccm1, were clearly detected within meningeal and parenchymal cortical vessels at P8. This expression was no more detected by P19 and in adult murine brain, strongly suggesting a role for these 2 proteins in the intensive angiogenesis process occuring within the central nervous system during this period.
Collapse
|
30
|
Abstract
The past few years have seen rapid advances in our understanding of the genetics and molecular biology of cerebral cavernous malformations (CCM). This article summarizes the recent cloning of the CCM1, CCM2, and CCM3 genes, which are responsible for autosomal dominant CCM, and also describes current hypotheses for their roles in integrin and p38 mitogen-activated protein kinase- mediated regulation of angiogenesis. A mouse model of CCM has been generated by mutation of the Ccm1 gene, and it indicates a role for that protein in arterial development. Future studies will probably focus on integration of data from each of the three CCM genes into a single model of the pathogenesis of cavernous malformation.
Collapse
Affiliation(s)
- Nicholas W Plummer
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Box 3175, Durham, NC 27710, USA
| | | | | |
Collapse
|
31
|
Raychaudhuri R, Batjer HH, Awad IA. Intracranial cavernous angioma: a practical review of clinical and biological aspects. ACTA ACUST UNITED AC 2005; 63:319-28; discussion 328. [PMID: 15808709 DOI: 10.1016/j.surneu.2004.05.032] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2003] [Accepted: 05/17/2004] [Indexed: 10/25/2022]
Abstract
BACKGROUND Cavernomas are an uncommon lesion seen in neurosurgical practice that can occasionally rupture. Recent developments in neurosurgical technique and microbiology have brought greater insight into the treatment and molecular pathogenesis of cavernoma. In this review, a historical overview of cavernous angioma, a current paradigm for treatment, promising new molecular biological developments, and suggestions for future directions in neurosurgical research are presented, with emphasis on practical clinical applications. METHODS A survey of the literature on cavernous angioma and consultation with the Department of Neurosurgery at Northwestern Memorial Hospital was conducted by the authors to gain greater insight regarding this lesion. Papers and consultation revealed the importance of careful evaluation of this lesion, new techniques such as functional magnetic resonance imaging and frameless stereotaxy that simplify clinical management of cavernomas, and potential mechanisms by which to tackle this lesion in the future. New basic knowledge on disease biology is summarized with practical applications in the clinical arena. RESULTS There appear to be a number of controversies regarding management of this lesion. These include risk factors faced by the patient, controversy over the importance of resection, and modality through which the treatment should occur. An algorithm is presented to aid the neurosurgeon in management of these lesions. CONCLUSIONS Exciting developments in neurosurgery and molecular biology will continue to have a major impact on clinical treatment of this disease. Unresolved issues regarding the importance of certain risk factors, the role for radiotherapy in treatments, and the underlying molecular abnormalities must be tackled to gain greater clarity in treatment of this lesion.
Collapse
Affiliation(s)
- Ratul Raychaudhuri
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | | | | |
Collapse
|
32
|
Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, Coubes P, Echenne B, Ibrahim R, Irthum B, Jacquet G, Lonjon M, Moreau JJ, Neau JP, Parker F, Tremoulet M, Tournier-Lasserve E. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005; 76:42-51. [PMID: 15543491 PMCID: PMC1196432 DOI: 10.1086/426952] [Citation(s) in RCA: 319] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2004] [Accepted: 10/11/2004] [Indexed: 11/03/2022] Open
Abstract
Cerebral cavernous malformations (CCMs) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. They cause seizures and cerebral hemorrhages, which can result in focal neurological deficits. Three CCM loci have been mapped, and loss-of-function mutations were identified in the KRIT1 (CCM1) and MGC4607 (CCM2) genes. We report herein the identification of PDCD10 (programmed cell death 10) as the CCM3 gene. The CCM3 locus has been previously mapped to 3q26-27 within a 22-cM interval that is bracketed by D3S1763 and D3S1262. We hypothesized that genomic deletions might occur at the CCM3 locus, as reported previously to occur at the CCM2 locus. Through high-density microsatellite genotyping of 20 families, we identified, in one family, null alleles that resulted from a deletion within a 4-Mb interval flanked by markers D3S3668 and D3S1614. This de novo deletion encompassed D3S1763, which strongly suggests that the CCM3 gene lies within a 970-kb region bracketed by D3S1763 and D3S1614. Six additional distinct deleterious mutations within PDCD10, one of the five known genes mapped within this interval, were identified in seven families. Three of these mutations were nonsense mutations, and two led to an aberrant splicing of exon 9, with a frameshift and a longer open reading frame within exon 10. The last of the six mutations led to an aberrant splicing of exon 5, without frameshift. Three of these mutations occurred de novo. All of them cosegregated with the disease in the families and were not observed in 200 control chromosomes. PDCD10, also called "TFAR15," had been initially identified through a screening for genes differentially expressed during the induction of apoptosis in the TF-1 premyeloid cell line. It is highly conserved in both vertebrates and invertebrates. Its implication in cerebral cavernous malformations strongly suggests that it is a new player in vascular morphogenesis and/or remodeling.
Collapse
Affiliation(s)
- F. Bergametti
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - C. Denier
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - P. Labauge
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Arnoult
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - S. Boetto
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Clanet
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - P. Coubes
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - B. Echenne
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - R. Ibrahim
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - B. Irthum
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - G. Jacquet
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Lonjon
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - J. J. Moreau
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - J. P. Neau
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - F. Parker
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Tremoulet
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - E. Tournier-Lasserve
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | | |
Collapse
|
33
|
Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. THE AMERICAN JOURNAL OF PATHOLOGY 2004; 165:1509-18. [PMID: 15509522 PMCID: PMC1618670 DOI: 10.1016/s0002-9440(10)63409-8] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Cerebral cavernous malformations (CCM) consist of clusters of abnormally dilated blood vessels. Hemorrhaging of these lesions can cause seizures and lethal stroke. Three loci are associated with autosomal dominant CCM, and the causative genes have been identified for CCM1 and CCM2. We have generated mice with a targeted mutation of the Ccm1 gene, but an initial survey of 20 heterozygous mice failed to detect any cavernous malformations. To test the hypothesis that growth of cavernous malformations depends on somatic loss of heterozygosity at the Ccm1 locus, we bred animals that were heterozygous for the Ccm1 mutation and homozygous for loss of the tumor suppressor Trp53 (p53), which has been shown to increase the rate of somatic mutation. We observed vascular lesions in the brains of 55% of the double-mutant animals but none in littermates with other genotypes. Although the genetic evidence suggested somatic mutation of the wild-type Ccm1 allele, we were unable to demonstrate loss of heterozygosity by molecular methods. An alternative explanation is that p53 plays a direct role in formation of the vascular malformations. The striking similarity of the human and mouse lesions indicates that the Ccm1(+/-) Trp53(-/-) mice are an appropriate animal model of CCM.
Collapse
Affiliation(s)
- Nicholas W Plummer
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
| | | | | | | | | | | |
Collapse
|
34
|
Marini V, Ferrera L, Pigatto F, Origone P, Garrè C, Dorcaratto A, Viale G, Alberti F, Mareni C. Search for loss of heterozygosity and mutation analysis of KRIT1 gene in CCM patients. Am J Med Genet A 2004; 130A:98-101. [PMID: 15368504 DOI: 10.1002/ajmg.a.30122] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
35
|
Guzeloglu-Kayisli O, Amankulor NM, Voorhees J, Luleci G, Lifton RP, Gunel M. KRIT1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex. Neurosurgery 2004; 54:943-9; discussion 949. [PMID: 15046662 DOI: 10.1227/01.neu.0000114512.59624.a5] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2003] [Accepted: 11/17/2003] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE Mutations in KRIT1 cause familial cerebral cavernous malformation, an autosomal dominant disorder affecting primarily the central nervous system vasculature. Although recent studies have suggested that Krev-1 interaction trapped 1 (KRIT1) is a microtubule-associated protein that interacts with integrin cytoplasmic domain-associated protein-1alpha, the function of KRIT1 remains elusive. METHODS We used Western blotting and immunohistochemistry with specific KRIT1 polyclonal antibodies to investigate KRIT1 protein expression in diverse cerebral and extracerebral tissues. RESULTS Immunostaining demonstrates that although KRIT1 is expressed in a broad variety of human organs, it localizes to the vascular endothelium of each, specifically to capillaries and arterioles. KRIT1 antibody fails to stain fenestrated capillaries in the kidney, the liver, or the red pulp of the spleen, where endothelial cells do not to adhere to one another. In contrast, intense staining is observed in the thymus and the white pulp of the spleen, where specialized blood-organ barriers are formed. Other cell types, including various epithelia, cardiac myocytes, and hepatocytes, also stain with KRIT1. CONCLUSION Although KRIT1 expression is seen in every endothelium studied, cerebral cavernous malformation lesions are seen almost exclusively in the central nervous system, suggesting that additional cell type(s) contribute to the pathophysiology of cerebral cavernous malformations. Here, we demonstrate that KRIT1 is also present in cells and structures integral to the cerebral angiogenesis and formation of the blood-brain barrier, namely, endothelial cells and astrocytic foot processes, as well as pyramidal neurons in the cerebral cortex.
Collapse
MESH Headings
- Adult
- Astrocytes/pathology
- Blotting, Western
- Brain Neoplasms/genetics
- Brain Neoplasms/pathology
- Brain Neoplasms/surgery
- Cerebral Cortex/pathology
- Chromosome Aberrations
- Endothelium, Vascular/pathology
- Gene Expression Regulation, Neoplastic/physiology
- Genes, Dominant/genetics
- Hemangioma, Cavernous/genetics
- Hemangioma, Cavernous/pathology
- Hemangioma, Cavernous, Central Nervous System/genetics
- Hemangioma, Cavernous, Central Nervous System/pathology
- Hemangioma, Cavernous, Central Nervous System/surgery
- Humans
- Immunoenzyme Techniques
- KRIT1 Protein
- Microtubule-Associated Proteins/genetics
- Proto-Oncogene Proteins/genetics
- Pyramidal Cells/pathology
Collapse
Affiliation(s)
- Ozlem Guzeloglu-Kayisli
- Neurovascular Surgery Program, Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
| | | | | | | | | | | |
Collapse
|
36
|
Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development 2004; 131:1437-48. [PMID: 14993192 DOI: 10.1242/dev.01036] [Citation(s) in RCA: 172] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Hemorrhagic stroke is a significant cause of morbidity and mortality in children, and is frequently associated with intracranial vascular malformations. One prevalent form of these vascular malformations, cerebral cavernous malformation, is characterized by thin-walled vascular cavities that hemorrhage and has been linked to loss-of-function mutations in CCM1. The neural and epithelial expression of CCM1 in adulthood suggests that cavernous malformations may be the result of primary neural defects. In this study, we generated mice lacking Ccm1 and demonstrate that Ccm1 is ubiquitously expressed early in embryogenesis and is essential for vascular development. Homozygous mutant embryos die in mid-gestation and the first detectable defects are exclusively vascular in nature. The precursor vessels of the brain become dilated starting at E8.5, reminiscent of the intracranial vascular defects observed in the human disease. In addition, there is marked enlargement and increased endothelial proliferation of the caudal dorsal aorta, as well as variable narrowing of the branchial arch arteries and proximal dorsal aorta. These vascular defects are not secondary to primary neural defects, as neural morphology and marker expression are normal even subsequent to the onset of vascular pathology. The defects in the vascular structure of embryos lacking Ccm1 are associated with early downregulation of artery-specific markers, including the Efnb2- and Notch-related genes. Finally, consistent with the murine data, we found that there is an analogous reduction in Notch gene expression in arterioles from humans with mutations in CCM1. Our studies suggest that cavernous malformations result from primary vascular rather than neural defects.
Collapse
Affiliation(s)
- Kevin J Whitehead
- Program in Human Molecular Biology and Genetics, University of Utah, Building 533 Room 4220, 15 N 2030 East, Salt Lake City, Utah 84112, USA
| | | | | | | | | |
Collapse
|
37
|
Retta SF, Avolio M, Francalanci F, Procida S, Balzac F, Degani S, Tarone G, Silengo L. Identification of Krit1B: a novel alternative splicing isoform of cerebral cavernous malformation gene-1. Gene 2004; 325:63-78. [PMID: 14697511 DOI: 10.1016/j.gene.2003.09.046] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Cerebral cavernous malformations (CCM) are vascular malformations, mostly located in the central nervous system, which occur in 0.1-0.5% of the population. They are characterized by abnormally enlarged and often leaking capillary cavities without intervening neural parenchyma. Some are clinically silent, whereas others cause seizures, intracerebral haemorrhage or focal neurological deficits. These vascular malformations can arise sporadically or may be inherited as an autosomal dominant condition with incomplete penetrance. At least 45% of families affected with cerebral cavernous malformations harbour a mutation in Krev interaction trapped-1 (Krit1) gene (cerebral cavernous malformation gene-1, CCM1). This gene contains 16 coding exons which encode a 736-amino acid protein containing three ankyrin repeats and a FERM domain. Neither the CCM1 pathogenetic mechanisms nor the function of the Krit1 protein are understood so far, although several hypotheses have been inferred from the predicted consequences of Krit1 mutations as well as from the identification of Krit1 as a binding partner of Rap1A, ICAP1A and microtubules. Here, we report the identification of Krit1B, a novel Krit1 isoform characterized by the alternative splicing of the 15th coding exon. We show that the Krit1B splice isoform is widely expressed in mouse cell lines and tissues, whereas its expression is highly restricted in human. In addition, we developed a real-time PCR strategy to accurately quantify the relative ratio of the two Krit1 alternative transcripts in different tissues, demonstrating a Krit1B/Krit1A ratio up to 20% in mouse thymus, but significantly lower ratios in other tissues. Bioinformatic analysis using exon/gene-prediction, comparative alignment and structure analysis programs supported the existence of Krit1 alternative transcripts lacking the 15th coding exon and showed that the splicing out of this exon occurs outside of potentially important Krit1 structural domains but in a region required for association with Rap1A, suggesting a subtle, yet important effect on the protein function. Our results indicate that maintenance of a proper ratio between Krit1A and Krit1B could be functionally relevant and suggest that the novel Krit1B isoform might expand our understanding of the role of Krit1 in CCM1 pathogenesis.
Collapse
Affiliation(s)
- Saverio Francesco Retta
- Department of Genetic, Biology and Biochemistry, University of Torino and Experimental Medicine Research Centre, San Giovanni Battista Hospital, Via Santena 5/bis, 10126 Turin, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, Verlaan D, Balogun F, Hughes L, Leedom TP, Plummer NW, Cannella M, Maglione V, Squitieri F, Johnson EW, Rouleau GA, Ptacek L, Marchuk DA. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 2003; 73:1459-64. [PMID: 14624391 PMCID: PMC1180409 DOI: 10.1086/380314] [Citation(s) in RCA: 256] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2003] [Accepted: 09/18/2003] [Indexed: 11/03/2022] Open
Abstract
Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. Mutations in the gene KRIT1 are responsible for type 1 CCM (CCM1). We report that a novel gene, MGC4607, exhibits eight different mutations in nine families with type 2 CCM (CCM2). MGC4607, similar to the KRIT1 binding partner ICAP1alpha, encodes a protein with a phosphotyrosine-binding domain. This protein may be part of the complex pathway of integrin signaling that, when perturbed, causes abnormal vascular morphogenesis in the brain, leading to CCM formation.
Collapse
Affiliation(s)
- Christina L. Liquori
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Michel J. Berg
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Adrian M. Siegel
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Elizabeth Huang
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Jon S. Zawistowski
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - T’Prien Stoffer
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Dominique Verlaan
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Fiyinfolu Balogun
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Lori Hughes
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Tracey P. Leedom
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Nicholas W. Plummer
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Milena Cannella
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Vittorio Maglione
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Ferdinando Squitieri
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Eric W. Johnson
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Guy A. Rouleau
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Louis Ptacek
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| | - Douglas A. Marchuk
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; Strong Epilepsy Center, Department of Neurology, University of Rochester Medical Center, Rochester, NY; Department of Neurology, University Hospital Zurich, Zurich; Barrow Neurological Institute, Neurogenetics, Phoenix; Montreal General Hospital, Department of Neurology, Montreal; Neurogenetics Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Neuromed, Pozzilli, Italy; and University of California, San Francisco, Department of Neurology, San Francisco
| |
Collapse
|